

## LIST OF TABLES

<b>Table</b>	<b>page</b>
(1) Comparison between the two studied groups according to the age & gender.	23
(2) Comparison between the two studied groups according to preexisting conditions.	25
(3) Comparison between the two studied groups according to vital signs on admission	27
(4) Comparison between the two studied groups according to APACHI II & SOFA scores on admission	30
(5) Descriptive analysis of the studied cases according to ABG on admission	31
(6) Descriptive analysis of the studied cases according to lab investigations on admission (n=100)	31
(7) Comparison between Group I and Group II regarding sites of infection	32
(8) Distribution of the studied cases according to the causes of infection in studied population.	34
(9) Distribution of the studied cases according to AKIN	35
(10) Descriptive analysis of the studied cases according to creatinine level	36
(11) Comparison between the studied groups with Ang./Cr. Ratio (ng /mg) regarding Creatinine level on admission	37
(12) Agreement (sensitivity, specificity and accuracy) for Urinary Ang. / Cr. ratio to predict AKI	39
(13) Correlation between Ang. /Cr. Ratio on admission and AKIN staging in each day.	40
(14) Correlation between Ang. /Cr. Ratio on admission and Cr. level in each day	40
(15) Distribution of the studied groups' outcomes according to urinary Ang./ Cr. Ratio grouping	41
(16) Distribution of the studied group's outcomes according AKIN staging	42
(17) Relation between Ang. /Cr. ratio (ng/mg) and outcomes of Group II	43
(18) Agreement (sensitivity, specificity and accuracy) for Ang. / Cr. ratio to predict RRT requirement in Group II	44
(19) Agreement (sensitivity, specificity and accuracy) of Ang./Cr. ratio (ng/mg) for predicting mortality in Group II	45

## LIST OF FIGURES

Figure	page
(1) Key potential pathways implicated in pathogenesis of acute kidney injury due to ischemia or sepsis	5
(2) pathophysiology of ischemic of acute kidney injury	8
(3) The pathophysiologic mechanisms of reduction of GFR in ATN	9
(4) New spectrum of AKI based on combination of functional and damage biomarkers.	11
(5) Comparison between Group I and Group II according to gender.	24
(6) Comparison between Group I and Group II according to age.	24
(7) Comparison between Group I and Group II regarding preexisting conditions. D.M, diabetes mellitus; HTN, hypertension; I.H.D, ischemic heart disease; COPD, chronic obstructive pulmonary disease.	26
(8) Comparison between the two studied groups according to Mean BP (mmHg)	28
(9) Comparison between the two studied groups according to RR (cycle/min)	28
(10) Comparison between the two studied groups according to Temperature °C	29
(11) Comparison between the two studied groups according to HR (beat/min)	29
(12) Comparison between the two studied groups according to APACHI II & SOFA scores	30
(13) Comparison between Group I and Group II regarding site of infection	33
(14) Distribution of the studied cases according to median AKIN score	35
(15) Descriptive analysis of the studied cases according to mean creatinine level	36
(16) Comparison between group I and group II regarding Ang./Cr. Ratio (ng /mg) on admission	37
(17) Comparison between group I and group II regarding creatinine level on admission	38
(18) ROC curve for Ang. /Cr. ratio on admission to predict AKI	39
(19) Distribution of the studied groups' outcomes according to urinary Ang./ Cr. Ratio grouping	41
(20) Distribution of the studied group's outcomes according AKIN staging	42
(21) Distribution of Group II outcomes	44
(22) ROC curve for Ang. /Cr. ratio to predict RRT requirement in Group II	45
(23) ROC curve for Ang. /Cr. ratio (ng/mg) to predict mortality in Group II	46

## LIST OF ABBREVIATIONS

<b>ACCP</b>	: American College of Chest Physicians
<b>ACEI</b>	: Angiotensin-Converting Enzyme Inhibitor
<b>ADQI</b>	: Acute Dialysis Quality Initiative
<b>AGT</b>	: Angiotensinogen
<b>AKD</b>	: Acute Kidney Disease
<b>AKI</b>	: acute kidney injury
<b>AKIN</b>	: Acute Kidney Injury staging
<b>ALI</b>	: Acute Lung Injury
<b>ALT</b>	: Alanine Amino Transferase
<b>Ang I</b>	: Angiotensin I
<b>Ang II</b>	: Angiotensin II
<b>APACHE II</b>	: Acute Physiological and Chronic Health Evaluation-II
<b>ARB</b>	: Angiotensin Receptor Blocker
<b>ARF</b>	: Acute Renal Failure
<b>AST</b>	: Aspartate Amino Transferase
<b>AT1 receptor</b>	: Angiotensin Receptor 1
<b>ATN</b>	: Acute Tubular Necrosis
<b>ATS</b>	: American Thoracic Society
<b>AUC</b>	: Area under the Curve
<b>CKD</b>	: Chronic Kidney Disease
<b>COPD</b>	: Chronic Obstructive Pulmonary Disease
<b>DM</b>	: Diabetes Mellitus
<b>ELISA</b>	: Enzyme-Linked Immunosorbent Assay
<b>ESICM</b>	: European Society of Intensive Care Medicine
<b>F<sub>E</sub>Na</b>	: Fractional Excretion of Sodium
<b>GCS</b>	: Glasgow Coma Score
<b>GFR</b>	: Glomerular Filtration Rate

<b>HTN</b>	: Hypertension
<b>ICU</b>	: Intensive Care Unit
<b>IHD</b>	: Ischemic Heart Disease
<b>IL-18</b>	: Interleukin-18
<b>INR</b>	: International normalization ratio
<b>KDIGO</b>	: Kidney Disease Improving Global Outcomes
<b>KIM-1</b>	: Kidney Injury Molecule -1
<b>L-FABP</b>	: Liver-type fatty acid-binding protein
<b>MTAL</b>	: Medullary Thick Ascending Limb of The Loop Of Henle
<b>MAP</b>	: Mean Blood Pressure
<b>MODS</b>	: Multi Organ Dysfunction Syndrome
<b>NF-<math>\kappa</math>B</b>	: Nuclear Factor $\kappa$ B
<b>NGAL</b>	: Neutrophil Gelatinase Associated Lipocalin
<b>NO</b>	: Nitric Oxide
<b>NSAIDs</b>	: Nonsteroidal Anti-Inflammatory Drugs
<b>RAS</b>	: Renin Angiotensin System
<b>RIFLE</b>	: Risk, Injury, Failure, Loss of function, End stage
<b>ROC</b>	: Receiver Operating Characteristic
<b>RRT</b>	: Renal Replacement Therapy
<b>S Cr</b>	: Serum Creatinine
<b>SBP</b>	: Systolic Blood Pressure
<b>SCCM</b>	: Society of Critical Care Medicine
<b>SD</b>	: Standard Deviation
<b>SIRS</b>	: Systemic Inflammatory Response Syndrome
<b>SIS</b>	: Surgical Infection Society
<b>SOFA</b>	: Sequential Organ Failure Assessment
<b>uAnCR</b>	: Urinary Angiotensinogen / Creatinine Ratio
<b>UOP</b>	: Urine Out Put
<b><math>\pi</math>-GST</b>	: A-Glutathione S-Transferase